

Immunohistochemical stainers

Overview Pros and Cons

Ole Nielsen, Dept. of Pathology Odense University Hospital

> With compliments to Søren Nielsen, NQC Scheme manager, 2003-2016





This lecture is meant to be a basis for an open discussion... and not an attempt to promote any stainer / company











Clinica Chimica Acta 278 (1998) 185-192

Comparative evaluation of automated systems in immunohistochemistry

T. Le Neel^a, A. Moreau^b, C. Laboisse^b, A. Truchaud^{a,*}

^aEngineering Laboratory, Institute of Biology, 9 Quai Moncousu, 44093 Nantes, France ^bLaboratory of Pathology, Institute of Biology, 9 Quai Moncousu, 44093 Nantes, France

Product focus

A review of automated slide stainers for IHC and ISH

By Joe Myers, MS, CT(ASCP)

2: http://www.mlo-online.com/articles/201207/automated-ihc-ish-slide-staining-systems.php



CHAPTER 9

THE PROS AND CONS OF AUTOMATION FOR IMMUNOHISTOCHMISTRY FROM THE PROSPECTIVE OF THE PATHOLOGY LABORATORY

DAVID G. HICKS and LORALEE MCMAHON

2010

Part II: The Potentials and Pitfalls

Chapter 9

Automation in IHC

Ole Feldballe Rasmussen, PhD, MSc



2013



IHC Guidebook Sixth Edition



Immunohistochemical Staining Methods





1	Quality Management and Regulation Jeffrey Prichard	1
2	Technique and Troubleshooting of Antibody Testing Fan Lin and Jianhui Shi	17
3	Overview of Automated Immunohistochemistry Jeffrey Prichard, Angela Bitting, and Joe Myers	23
4	Automated Staining: Dako Perspective Ole F. Rasmussen and Andreas Schønau	31
5	Automated Staining: Ventana Perspective Angela Sattler	37
6	Tissue Microarray Myra Wilkerson and Erin Powell	45

Fan Lin Jeffrey Prichard *Editors*

Haiyan Liu Myra Wilkerson Conrad Schuerch Assoc. Editors

Handbook of Practical Immunohistochemistry

Springer

Frequently Asked Questions

Overview of Automated Immunohistochemistry

Jeffrey W. Prichard, DO

• Context.—The increasing demand for immunohistochemistry for clinical diagnostics, in combination with an ongoing shortage of staff in the histology laboratory, has brought about a need for automation in immunohistochemistry. The current automated staining platforms vary significantly in their design and capabilities.

Objective.—To review how technology has been applied to automating the process of immunohistochemical staining.

Data Sources.—Literature review, vendor interviews, and personal practice experience.

2015

Conclusions.—Each of the commercially available, automated immunohistochemistry platforms has strategic design differences that produce advantages and disadvantages. Understanding those differences can help match the demands of testing volumes, turnaround time, standardization, and labor savings to the appropriate automated instrumentation.

(Arch Pathol Lab Med. 2014;138:1578–1582; doi: 10.5858/arpa.2014-0083-RA)



Immunohistochemical staining procedure is a multiplex technique requiring a lot of hands-on when performed manually.

From deparaffination to counterstaining the IHC procedure at minimum requires 60-100 manual interactions and handling procedure on each slide to be stained. Capacity ?? (50-100 slides pr tech.*)

Preparation – sorting, deparaffination, epitope retrieval.... Application of reagents - pippettingSecure even distribution – "Pap-pen"Avoid evaporation / secure moist – staining trays

* Haines DM, Chelack BJ. Technical considerations for developing enzyme immunohistochemical staining procedures on formalinfixed paraffin-embedded tissue for diagnostic pathology. J Vet Diagn Invest 1991; 3:101-12





Manual staining: Wash – Dry – Apply Wash – Dry – Apply Wash....

Challenge: Time, Standardisation, Traceability, Skills...







ER assessments	2003 B8 (n=154)	2017 B23 (n=398)
Manual performance	5%	4%
Semi automated system	89%	18%
Fully automated system	6%	78%



ER assessments	2003 B8 (n=154)	2017 B23 (n=398)
Manual performance	5%	4%
Semi automated system	89%	18%
Fully automated system	6%	78%

Performance history

This was the sixteenth NordiQC assessment of ER. The proportion of sufficient results was similar compared to the latest run (see Figure 1).

Fig. 1. Participant numbers and pass rates for ER during 16 runs



Caution: 2003

Introduction of new rmAb's and detectionsystems in the same period







Automation of the IHC staining procedure:

- To secure and improve consistency of the IHC assay compared to manual performance; intra- and interlaboratory
- 2. Reduce the technician workload used for IHC
- 3. Improve IHC testing capacity
- 4. Traceability / tracking of events

Key-driver: Automation = standardization



History of IHC automation:

Started in the late 80's

Various semiautomated systems (No depar or HIER)



Fig. 1. Automation of IHC – Principles (a) top-down capillarity, (b) ascendant capillarity, (c) flat immunohistolabelling.

A: Cadenza, Shandon B: TechMate, Dako C: ES, Ventana

IHC – Immunohistochemical stainers The first generation stainers - late 80's







TechMate, Dako



Most commonly used semi-automated stainers





Autostainer, Dako (Plus, 48Link)

Autostainer, LabVision (36/48/72)

Parallel processing

1. Depar / dehydration / HIER – separately to IHC e.g. PT-module

2. IHC performed by stainer – blocking of enzyme to counterstaining



Fully automated stainers Performs:

- Deparaffination
- Epitope retrieval (HIER and/or proteolysis)

6

- IHC protocol
- Counterstaining





Fully automated stainers

Stainer	Company	Principle	Capacity
BenchMark Ultra	Ventana/Roche	Flat labelling	30 slides
Bond III/Max	Leica	Capillary	30 slides
OMNIS	Dako/Agilent	Dynamic capillary	60 slides
Oncore	Biocare	Kinetic chamber	36 slides
Tissue-Tek Genie	Sakura	Capillary	30 slides
Xmatrx ELITE	BioGenex	Flat labelling / Micro-chamber	40 slides



Which instrument should I choose?

- Functionality
- Workload
- Workflow
- Flexibility
- Cost





Overview of Automated Immunohistochemistry

Jeffrey W. Prichard, DO

• Context.—The increasing demand for immunohistochemistry for clinical diagnostics, in combination with an ongoing shortage of staff in the histology laboratory, has brought about a need for automation in immunohistochemistry. The current automated staining platforms vary significantly in their design and capabilities.

Objective.—To review how technology has been applied to automating the process of immunohistochemical staining.

Data Sources.—Literature review, vendor interviews, and personal practice experience.

Conclusions.—Each of the commercially available, automated immunohistochemistry platforms has strategic design differences that produce advantages and disadvantages. Understanding those differences can help match the demands of testing volumes, turnaround time, standardization, and labor savings to the appropriate automated instrumentation. (Arch Pathol Lab Med. 2014;138:1578–1582; doi: 10.5858/arpa.2014-0083-RA)

"If you understand the needs of your laboratory and the capabilities of the various systems, you can find the best fit for your laboratory."

"If an automated IHC platform is chosen correctly to match the demands of testing, automation can provide necessary process improvement and cost savings needed in the modern practice of pathology."

"When evaluating automated staining systems, the first thing to understand is that there is no, one "best system" on the market, for all purposes."



Automation of the staining procedure: Functionality

- Baking of slides
- Deparaffination
- Pre-treatment HIER and proteolysis
- Combined retrieval HIER+proteolysis / proteolysis+HIER
- Continuous loading
- Batch loading
- IHC / ISH ?
- Coverslipping
- Temperature controlled slides, reagents
- Waste handling amount, separation
- Requirement of special utensiles containers, slides
- Others



Automation of the staining procedure: Workload/workflow

- Capacity pr run, .. day, .. week (no of units back-up..)
- Place, start and walk
 - Interactions required e.g. chromogen stability
- Sequential process
 - One instrument for all steps
- Parallel process
 - e.g. one instrument for HIER, one instrument for IHC
- Batch versus continuous load of slides
 - "Whole" working process in dept must be incorporated
- Technician ressources for maintenance
 - Frequency, extent, safety etc



Automation of the staining procedure: Flexibility

Software

- Protocol set-up
 - HIER settings time, temperature
 - Retrieval methods single, combined
 - Adjustment of incubation times Ab, detection, etc
 - Adjustment of incubation temp Ab, proteolysis
 - Adjustment of protocol sequence H202 etc
 - Adjustment of reagent volume
 - Modification of protocol steps addition/removal
 - Washing conditions of low affinity Abs



Automation of the staining procedure: Flexibility

Reagents (I)

- HIER reagents
 - How many and which HIER bufferes are offered ?
 - Can 3' party HIER bufferes be applied ?

Proteolysis

- Which proteolytic enzymes are offered
- Can 3' party enzymes be applied
- Primary antibody
 - 3' party antibodies ?
 - RTU antibodies available ?



Automation of the staining procedure: Flexibility

Reagents (II)

- Detection systems
 - Can 3' party detection system be applied ?
 - Reactivity mouse-rabbit and other species ?
 - Universal (MR), mono-specific ?
 - Modularity can sensitivity be adjusted ?
 - Amplification step, Linker, different systems etc
- Dual staining capabilities
 - Are different chromogens offered from vendor
 - Can 3' party chromogens be applied ?
 - Simultaneously ? (mono-specific system required)
 - Sequential ?



Automation of the staining procedure: Costs

- Direct costs
 - Price pr instrument
 - Price pr slide
 - Preventive maintenance
- Indirect costs
 - Waste volumen
 - Daily maintenance (time used)
- "Hidden costs"
 - Down-period what is expected and accepted ?
 - Re-runs what is expected and accepted ?
 - Assesscories needed/required
 - Empty vials for reagents, reagents, amp/linker, etc



	Autost. Dako/TFS	Intellip. Biocare	Oncore Biocare	Impath Pathc.	BOND III Leica	Bench. U VMS	Omnis Dako
Capacity	48/36-72	50	36	36	30	30	60
Reagents	64	48	40	40	36	35	60
Volume	200 ul	300 ul	200 ul	200 ul	150 ul	100 ul	200 ul
Adjustab.	Yes	Yes	Yes	Yes	Yes	No	No
Depar.	No	No	Yes	Yes	Yes	Yes	Yes
HIER	No	No	Yes	Yes	Yes	Yes	Yes
HIER buf. 3' part	- Yes	- Yes	2 No	2 No	2 No	2 No	5 Yes
Comb ret	Yes	Yes	?	?	Yes – H+P	Yes	Yes - H+P
3'part reagents	Ab, enz, det.,chr.	Ab, enz, det.,chr	Ab	No	Ab, enz	Ab, enz	Ab, enz, ,chr.
Any prot Any slide	Yes	Yes	Yes	Yes	No	Yes	No
Seq. DS	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Sim. DS	Yes	Yes	? (Yes)	? (Yes)	No	No	Yes
ISH	No	No	(Yes)	(Yes)	Yes	Yes	Yes



Fully-automated systems: BenchMark Ultra, Ventana

5 main Pros:

- 1. Place, start, walk
- 2. Continuous and/or batch loading "30 stainers"
- 3. Flexible protocol set-up e.g. combined retr.
- 4. Wide range of sensitivity for detection systems
- 5. IHC and ISH on same instrument / same slide..

- 1. Only CC1 applicable for HIER for IHC
- 2. Low affinity antibodies may show inferior performance
- 3. Maintenance time-consuming



Fully-automated systems: Bond, Leica

5 main Pros:

- 1. Place, start, walk
- 2. Flexible protocol set-up e.g. combined retr.
- 3. Both low and high affinity primary antibodies work
- 4. Easy to use loading, programming, maintenance
- 5. Wide portofolio of RTU antibodies plug-and-play

- 1. Covertile technique precipitates and weak hue
- 2. Less flexible regarding continuous start 3 x 10 slides
- 3. Limited portofolio of detection systems DAB & RED



Fully-automated systems: OMNIS, Dako

5 main Pros:

- 1. Flexible reagent choice HIER buffers
- 2. Easy to use loading, programming, maintenance
- 3. High capacity and daily throughput
- 4. IHC and ISH on same instrument
- 5. Temperature controlled reagents and protocols

- 1. Limited portofolio of RTUs & detection systems
- 2. Low affinity antibodies may show inferior performance
- 3. Less flexible protocol set-up



Fully-automated systems: Autostainer-LINK48, Dako

5 main Pros:

- 1. Flexible protocol set-up e.g. combined retr.
- 2. Flexible reagent choice HIER buffer, detection system
- 3. Both low and high affinity primary antibodies work
- 4. Easy to use loading, programming, maintenance
- 5. Wide portofolio of RTU antibodies plug-and-play

- 1. Increased manual interaction 2 instruments needed
- 2. Primarily batch operation
- 3. High reagent volumen needed 300 ul and >"dead-vol"



Automation in IHC reduces hands-on and improves consistency. However the quality of the end result is less influenced by the function of the automated stainer compared to the impact of:

- Quality of the tissue material (pre-analytics)
 - Automation will not compensate for delayed fixation etc.
- Quality of the reagents used (sensitivity, specificity analytics)
 Use of detection system with low sensitivity etc
- Accuracy of the technical optimization and validation of the test
 Use of RTU formats not adequately calibrated etc
- Interpretation of the test
 - Inadequate choice of control material etc



Cautions to be taken when comparing the different solutions:

E.g. cost for primary Ab – Was same or similar test conditions applied ??

	Bond-III	BenchMark Ultra	AS-48
ER, rmAb SP1	1:50	1:100	1:75
Ki67, mAb MiB1	1:100	1:200	1:200
Bcl2, mAb 124	1:100	1:25	1:100
CD10, mAb 56C6	1:20	1:40	1:40
CK-PAN, mAb AE1AE3	1:75	1:150	1:100
p504s, rmAb 13H4	1:100	1:100	1:150
Melan A, mAb A103	1:50	1:20	1:50
900\$ pr ml Ab:1 ul = 0.9\$ 1\$ = 6.5 DKK	HIER ER2, pH 9 20m 20m primary 3-step pol. – refine 150 ul Ab 2.7\$ pr slide	HIER CC1,pH 8.5 48m 32m primary 3-step mul. – OptiV. 100 ul Ab 1.9\$ pr slide	HIER TRS,pH 9, 20m 20m primary 3-step pol. – Flex+ 300 ul Ab 3.5\$ pr slide

Data from Dept. of Pathology, Aalborg University Hospital







Staining issues; TechMate – Staining gradient, imprint pattern – air bubbles





Staining issues; BenchMark, VMS – Uneven weak/neg areas – air bubbles





Staining issues; Bond, Leica – chromogen precipitates and general hue





Courtesy by Michael Bzorek



Staining issues; Omnis, Dako – chromogen precipitates





Staining issues; AS48, Dako – chromogen depletion or reagent not spread



PCK – slide no. 1



PCK – slide no. 2



Same reagents, same protocol, same block, same stainer

On-slide positive controls

Consider each slide position / chamber on the IHC stainer as an individual stainer and use appropriate on-slide controls



REVIEW ARTICLE

Standardization of Positive Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Committee

Emina E. Torlakovic, MD, PhD,*† Søren Nielsen, HT, CT,[‡]§ Glenn Francis, MBBS, FRCPA, MBA, FFSc (RCPA), I H John Garratt, RT, †** Blake Gilks, MD, FRCPC, † †† Jeffrey D. Goldsmith, MD, 1 Jason L. Hornick, MD, PhD, SS Elizabeth Hyjek, MD, PhD,* Merdol Ibrahim, PhD, || || Keith Miller, FIBMS, || || Eugen Petcu, MD, PhD, || Paul E. Swanson, MD, ¶¶## Xiaoge Zhou, MD, ***††† Clive R. Taylor, MD, PhD, ±±± and Mogens Vyberg, MD[†]§

TABLE 3. (continued)

	Special Considerations
Cut and submit "own on-slide control" if sending patients' unstained slides to another	The positive controls should match patients' sample tissue processing so far as is possible
laboratory for IHC testing	This is difficult if the sender does not know which IHC assays will be performed or if the sender does not have dIHC laboratory and has no positive controls
Use on-slide positive controls	"Run" or "batch" positive controls are not recommended
Date unstained slides with on-slide controls	Without the date when the slides are prepared, it will be impossible to determine if a unexpected weak result is due to variation in protocol or to an "expired" positive control

dIHC indicates diagnostic immunohistochemistry; iCAPCs, immunohistochemistry critical assay performance controls; SOP, standard operating procedure.



On-slide positive controls

"even for automated stainers, where it cannot be guaranteed that every slide in fact receives identical treatment".





FIGURE 1. Frequency of failed immunohistochemistry slides by category and platform.

2% error rate (452/22.234 slides) Class I 0,8% - Class II 9,0%

IHC indicates immunohistochemistry

or areas relevant to the test were missing (detached

during staining or paraffin block with control tissue

cut through)

Lab related (22%)

Category 1,2,3,4,7,8,10

Assay and/or Instrument (78%)





On-slide controls IHC slides stained for ALK (Class II), same run, same instrument, same protocol 14/19 passed 5/19 failed



Batch-control - Theoretically: Batch control fail by same conditions as above 0/19 passed 19/19 failed (no consistent internal control...)



Batch-control - Theoretically: Batch control pass by same conditions as above 19/19 passed 0/19 failed (the 5 failed slides not identified....)



Uneven Staining in Automated Immunohistochemistry: Cold and Hot Zones and Implications for Immunohistochemical Analysis of Biopsy Specimens

Carol C. Cheung, MD, PhD, JD,*† Paul E. Swanson, MD, ‡ Søren Nielsen, BMS, § Mogens Vyberg, MD, § and Emina E. Torlakovic, (Appl Immunohistochem Mol Morphol 2018;26:299–304)





Uneven Staining in Automated Immunohistochemistry: Cold and Hot Zones and Implications for Immunohistochemical Analysis of Biopsy Specimens

Carol C. Cheung, MD, PhD, JD,*† Paul E. Swanson, MD, ‡ Søren Nielsen, BMS, § Mogens Vyberg, MD, § and Emina E. Torlakovic, (Appl Immunohistochem Mol Morphol 2018;26:299–304)





Uneven Staining in Automated Immunohistochemistry: Cold and Hot Zones and Implications for Immunohistochemical Analysis of Biopsy Specimens

Carol C. Cheung, MD, PhD, JD,*† Paul E. Swanson, MD,‡ Søren Nielsen, BMS,§ Mogens Vyberg, MD,§ and Emina E. Torlakovic, (Appl Immunohistochem Mol Morphol 2018;26:299–304)











FIGURE 4. A, Small and medium sized cold zones are frequently circular. B, Hot zones are typically small and circular. C, Geographic areas with variable levels of decreased staining (1, moderate to severe; 2, mild). D, Despite the on-slide control (arrow) appearing to be "perfect," the entire patient test sample is affected by overstaining. E, Even when staining is significantly decreased, some evidence of a "positive" internal control can be detected, which may be misleading. F, Slide from the HepPar1 assay showing various patterns of uneven staining (arrows) including decreased lateral staining, small hot zones, as well as "vortex-like" decreased staining; areas that are central to the slide are most often most severely affected by "vortex-like" pattern (authors' observation; this parameter was not scored). G, Magnification of section \star from image (F) showing that both increased and decreased staining can be present in the same slide (arrows).







FIGURE 5. A slide stained for CDX2 with an on-slide control (OSC) in the control region (CR) and three serial sections of a needle core biopsy in region 1 (R1), region 2 (R2), region 3 (R3). A, Representative (high expressor) core from the OSC showing nuclear signal for CDX2 in colonic epithelium. B, Section of tumor in R1 showing nuclear positivity for CDX2. C, Serial section of tumor in R2 showing no signal for CDX2. C, Serial section of tumor in R3 showing no signal for CDX2.





"Results: Only 8% of slides showed completely uniform staining. Uneven staining (UES), including areas of both increased and decreased staining, occurred with all instruments. Decreased staining was often zonal, involving large regions of the slide. Decreased staining mostly localized in an instrument-dependent manner. Increased staining tended to occur in small foci with a random distribution. "

FIGURE 5. A slide stained for CDX2 with an on-slide control (OSC) in the control region (CR) and three serial sections of a needle core biopsy in region 1 (R1), region 2 (R2), region 3 (R3). A, Representative (high expressor) core from the OSC showing nuclear signal for CDX2 in colonic epithelium. B, Section of tumor in R1 showing nuclear positivity for CDX2. C, Serial section of tumor in R2 showing no signal for CDX2. C, Serial section of tumor in R3 showing no signal for CDX2.



"Results: Only 8% of slides showed completely uniform staining. Uneven staining (UES), including areas of both increased and decreased staining, occurred with all instruments. Decreased staining was often zonal, involving large regions of the slide. Decreased staining mostly localized in an instrument-dependent manner. Increased staining tended to occur in small foci with a random distribution."

B

"Conclusions: The common occurrence of UES (particularly decreased staining) has important implications for the reliable readout of IHC assays on biopsy samples. Baseline and periodic quality assurance testing for UES is recommended for all automated IHC instruments."

FIGURE 5. A slide stained for CDX2 with an on-slide control (OSC) in the control region (CR) and three serial sections of a needle core biopsy in region 1 (R1), region 2 (R2), region 3 (R3). A, Representative (high expressor) core from the OSC showing nuclear signal for CDX2 in colonic epithelium. B, Section of tumor in R1 showing nuclear positivity for CDX2. C, Serial section of tumor in R2 showing no signal for CDX2. C, Serial section of tumor in R3 showing no signal for CDX2.

IHC – Immunohistochemical stainers Conclusions:

Nord

- Automation in IHC is needed primarily to secure consistency of inter- and intralaboratory results and to reduce hands-on.
- There is no perfect system
 ² all have pros and cons. Each laboratory has to select the system being most applicable and favourable for the needs and demands within the laboratory.
- Use other laboratories to have a more objective view on the systems offered.
- Test for uneven staining* before choosing system.
- A combination of different systems might be the best solution, as the IHC tests can be performed on the system giving the best technical result and lowest price – drawback workflow....